Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Uniphar PLC ( (GB:UPR) ) has provided an announcement.
Uniphar plc, the Irish diversified healthcare services group, reported strong 2025 results, with revenue rising 11.0% to €3.07bn and gross profit up 7.0% to €457.7m, driven by double‑digit organic growth in its Pharma and Medtech divisions and solid gains in Supply Chain & Retail. The group’s organic gross profit growth of 8.9% was its fastest since IPO, supporting a 21% increase in adjusted EPS to 24.8 cent and extending a six‑year adjusted EPS CAGR of 16%.
EBITDA grew 6.0% to €130.9m, or 9.0% on an organic basis, while leverage remained moderate at 1.6x as Uniphar completed a €35m share buyback and delivered 99.1% free cash flow conversion. Strategic investments in a high‑tech Irish distribution hub, the TouchStore acquisition to strengthen digital pharmacy capabilities and continued ESG progress underpin management’s confidence in reaching its €200m EBITDA target by 2028, with most of that growth expected to be organic.
More about Uniphar PLC
Uniphar plc is a Dublin‑headquartered, international diversified healthcare services group serving more than 200 multinational pharmaceutical and medical technology manufacturers through three divisions: Pharma, Medtech and Supply Chain & Retail. Operating across Europe, North America, APAC and MENA and delivering into over 160 countries, it focuses on improving patient access to pharmaco‑medical products by connecting manufacturers with healthcare stakeholders.
Learn more about UPR stock on TipRanks’ Stock Analysis page.